Previous Close | 0.5899 |
Open | 0.5800 |
Bid | 0.5830 x 1000 |
Ask | 0.5935 x 1000 |
Day's Range | 0.5750 - 0.6084 |
52 Week Range | 0.4900 - 8.2470 |
Volume | |
Avg. Volume | 3,587,191 |
Market Cap | 85.892M |
Beta (5Y Monthly) | 1.85 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3610 |
Earnings Date | Aug 11, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.14 |
Subscribe to Yahoo Finance Plus to view Fair Value for ARDX
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on June 28, 2022, the compensation committee of the company's board of directors granted six new non-executive employees options to purchase an aggregate of 332,483 shares of the company's common stock, and granted an aggregate of 83,375 Restricted Stock Units (RSUs) to eight new
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the company may receive up to $20 million from HealthCare Royalty Partners (HealthCare Royalty) from the sale of its future royalties and sales milestones from Kyowa Kirin Co., Ltd (Kyowa Kirin), its collaboration partner in Japan for the commercialization of tenapanor for hyperp
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022. The Advisory Committee will discuss the company's New Drug Application